0
0
0
Summary
Latest filing:
Gerald W. McLaughlin is Director of Allarity Therapeutics, Inc. (ALLR). 1 SEC Form 4 filing on record, dated 7 May 2026.
Recent transactions
1The latest SEC Form 4 transaction reported by Gerald W. McLaughlin.
All1Awards1
Other insiders active in the same sector
No other insider has filed at Gerald W. McLaughlin's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Fairmount Funds Management LLC - $399.66M in SYRE purchases and sales in the last 12 months
- Robert M. Williams Jr. - $371.84M in AVAH purchases and sales in the last 12 months
- Paul R. Vigano - $371.84M in AVAH purchases and sales in the last 12 months
- August J. Troendle - $358.45M in MEDP purchases and sales in the last 12 months
- J.H. Whitney Equity Partners VII, LLC - $319.15M in AVAH purchases and sales in the last 12 months
- BAKER BROS. ADVISORS LP - $317.75M in CELC purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Gerald W. McLaughlin?
Gerald W. McLaughlin is a corporate insider, tracked as Director of Allarity Therapeutics, Inc. (ALLR). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Gerald W. McLaughlin last file a Form 4?
The only primary Form 4 on record is dated 7 May 2026.
